| 摘要 |
<p>The disclosure relates to apharmaceutical composition comprising glycopyrronium bromide at a dosage in the range of 0.5-100μg per actuation dissolved in an HFA propellant and a co-solvent such as ethanol, wherein said composition contains an amount of 1M hydrochloric acid (HCl) in the range of 0.005-1.0μg/μl. The composition may additionally comprises one or more pharmaceutically active ingredients selected from the group consisting of beta-2-agonists, corticosteroids, antimuscarinic agents, and phosphodiesterase (IV) inhibitors; wherein the beta-2 agonist is selected from the group of formoterol, salbutamol, fenoterol, carmoterol (TA 2005), indacaterol, milveterol, vilanterol (GSK 642444), terbultaline, salmeterol, bitolterol, metaproterenol all in form of single stereoisomers or mixtures thereof and salts thereof; wherein the corticosteroid is selected from the group of beclometasone dipropionate, fluticasone propionate, butixocort, mometasone fluroate, triamcinolone acetonide, budesonide and its 22R-epimer, ciclesonide, flunisolide, loteprednol, and rofleponide. These pharmaceutical compositions are suitable for use in the treatment or prophylaxis of respiratory diseases, such as chronic obstructive pulmonary disease (COPD).</p> |
